[{"id":"f9edf389-5ac1-4e51-b073-8c5312cec79c","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469982","created_at":"2026-03-28T01:43:35.285Z","updated_at":"2026-03-28T01:43:35.285Z","phase":"Phase 1","brief_title":"A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07469982","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-13"},{"id":"659160cb-410e-4379-bdd3-f303bb40e1fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05094336","created_at":"2021-10-26T20:53:08.844Z","updated_at":"2025-02-25T13:54:05.475Z","phase":"Phase 1/2","brief_title":"A Study of AMG 193 in Subjects With Advanced MTAP-[] Solid Tumors","source_id_and_acronym":"NCT05094336","lead_sponsor":"Amgen","biomarkers":" CDKN2A • MTAP","pipe":"","alterations":" ","tags":["CDKN2A • MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 649","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 08/02/2026","primary_completion_date":" 08/02/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-20"},{"id":"d4485f54-359c-4ee3-8554-f4f3c66c58bb","acronym":"TNG462-C101","url":"https://clinicaltrials.gov/study/NCT05732831","created_at":"2023-02-17T15:00:50.938Z","updated_at":"2025-02-25T14:41:52.620Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05732831 - TNG462-C101","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vopimetostat (TNG462)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-14"},{"id":"3aa72670-9b0b-4205-9807-1cc48204caf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05335941","created_at":"2022-04-20T16:53:38.622Z","updated_at":"2025-02-25T15:35:35.713Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma","source_id_and_acronym":"NCT05335941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-10"},{"id":"4f30abc8-8e7a-46eb-9dd2-cdd5a80eaef4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06810544","created_at":"2025-02-25T16:50:18.957Z","updated_at":"2025-02-25T16:50:18.957Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","source_id_and_acronym":"NCT06810544","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 191","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-05"},{"id":"15ebc24f-836d-4955-b1c1-9b9491f8cda7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895735","created_at":"2021-05-20T11:54:07.989Z","updated_at":"2024-07-02T16:34:26.348Z","phase":"Phase 2","brief_title":"Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer","source_id_and_acronym":"NCT04895735","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • MTAP • TYMS","pipe":" | ","alterations":" PD-L1 expression • TYMS expression","tags":["PD-L1 • MTAP • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 06/03/2025","primary_completion_date":" 06/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2024-06-13"},{"id":"6e960e10-a292-4eb9-ac61-0062dbf094ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05975073","created_at":"2023-08-03T15:09:55.318Z","updated_at":"2024-07-02T16:34:37.673Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors","source_id_and_acronym":"NCT05975073","lead_sponsor":"Amgen","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDE397 • AMG 193"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 12/03/2026","study_completion_date":" 12/03/2026","last_update_posted":"2024-06-06"},{"id":"f8a566d4-1220-4795-a41e-999d20763d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05245500","created_at":"2022-02-18T14:52:54.785Z","updated_at":"2024-07-02T16:34:59.606Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion","source_id_and_acronym":"NCT05245500","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navlimetostat (BMS‐986504)"],"overall_status":"Recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-06-03"},{"id":"a89145ed-d1fb-47bb-8570-547616d247d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275478","created_at":"2022-03-11T15:53:41.554Z","updated_at":"2024-07-02T16:34:59.862Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05275478","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNG908"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-31"},{"id":"92c00917-1e46-4b94-b994-56d21f87434a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04794699","created_at":"2021-03-12T16:52:33.483Z","updated_at":"2024-07-02T16:35:05.377Z","phase":"Phase 1","brief_title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","source_id_and_acronym":"NCT04794699","lead_sponsor":"IDEAYA Biosciences","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • albumin-bound paclitaxel • pemetrexed • Trodelvy (sacituzumab govitecan-hziy) • IDE397"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 03/30/2027","study_completion_date":" 03/30/2027","last_update_posted":"2024-05-07"},{"id":"59264190-7a26-482a-8591-2a0bf535a2e7","acronym":"NCI-2018-02517","url":"https://clinicaltrials.gov/study/NCT03744793","created_at":"2021-01-18T18:20:30.566Z","updated_at":"2024-07-02T16:35:16.094Z","phase":"Phase 2","brief_title":"Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer","source_id_and_acronym":"NCT03744793 - NCI-2018-02517","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Bavencio (avelumab) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-03-06"},{"id":"3c3237ce-b2fe-4d38-831f-297bf37b8861","acronym":"","url":"https://clinicaltrials.gov/study/NCT05312372","created_at":"2022-04-05T13:52:46.118Z","updated_at":"2024-07-02T16:35:59.449Z","phase":"Phase 1/2","brief_title":"S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC","source_id_and_acronym":"NCT05312372","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" PD-L1 • MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["PD-L1 • MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • S095033"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-12-07"},{"id":"d1253b91-fc27-48d4-8eda-23186b966e62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03361358","created_at":"2021-01-18T16:35:28.827Z","updated_at":"2024-07-02T16:36:48.342Z","phase":"","brief_title":"Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03361358","lead_sponsor":"Agios Pharmaceuticals, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S095033"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2019","primary_completion_date":" 09/30/2019","study_txt":" Completion: 09/30/2019","study_completion_date":" 09/30/2019","last_update_posted":"2020-03-16"}]